5.9. Other Assessments Coagulation data, urinalysis data, creatinine clearance, virology data, and human leukocyte antigen ( HLA) typing will be provided in by -subject data listings only. 5.10. Treatment Exposure Exposure to study treatment will be summarized overall and by cohort . Treatment duration summaries will be provided separately for CRS -207, Cy, and chemotherapy. The following study medication administrations will be summarized using descriptive statistics as well as categorical based on the number of administrations received (categories will be 1- 2 infusions, 3 -4 infusions, 5- 6 infusions, and > 6 infusions in the applicable summaries) : • Number of total CRS -207 doses received • Number of Cy administrations ( for Cohort 2 only ) • Number of pemetrexed doses administered (complete or partial) • Number of cisplatin , carboplatin, and total cisplatin/carboplatin doses administered (complete or partial) o The number of subjects who switched between cisplatin/carboplatin Aduro Biotech, Inc. CONFIDENTIAL Protocol ADU -CL-02 Final Version 1 Page 18 of 24 04MAY2018 Chemotherapy will also be presented categorically by 1- 2 cycles, 3 - 4 cycles, 5 - 6 cycles. The average volume of CRS -207 administered per subject will be summarized using descriptive statistics. The average will be calculated for each subject across all infusions then summarized overall and by cohort. Dose interruptions, incomplete administrations, and missed administrations will be included in the by -subject data listings. 5.11.